PolandGAOvsyannikovaIGKennedyRB.SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet2020; 396: 1595–1606.
2.
IaccarinoLBartoloniECarliL, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the italian multicentre registry. ClinExpRheumatol2015; 33: 449–456.
3.
McLaughlinPGrillo-LópezAJLinkBK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol1998; 16: 2825–2833.
4.
FurerVRondaanCHeijstekMW, et al. 2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis2020; 79: 39–52.
5.
Khayat-KhoeiMConwaySRubinsonDA, et al. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. J Neurol2021; 27: 1–3.
6.
SpieraRJinichSJannat-KhahD.Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. Epub ahead of print 11 May 2021.
